Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

Columnist Samuel Kirton talks with the Pulmonary Fibrosis Foundation's Amy Hajari Case, MD, about the Accelerate Research ...

What is Jascayd for pulmonary fibrosis? Jascayd (nerandomilast) is an approved oral therapy that’s intended to slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF) and ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed ...

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Birchbiomed’s FS2 (kynurenic acid) for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is ...

Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE ...

Cumberland Pharmaceuticals is launching a Phase 2 clinical trial to assess the safety and efficacy of its investigational therapy, ifetroban, in treating patients with idiopathic pulmonary fibrosis ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Musicians who play wind instruments are being warned of a potential hazard doctors have dubbed “bagpipe lung” — after a case study was published of a man who died of a lung condition known as ...